Ironwood Pharmaceuticals, Inc. - Q1 2011 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2011. Ironwood Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated medicines. Its lead product candidate, linaclotide, a guanylate cyclase type-C (GC-C) agonist, is in Phase 3 clinical development for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). The company operates in a single reportable segment: human therapeutics. In September 2010, the company sold its interest in its former subsidiary, Microbia, Inc., which is now reported as discontinued operations.
Key Financial Metrics
| Metric (in thousands) | Q1 2011 | Q1 2010 |
|---|---|---|
| Collaborative Arrangements Revenue | $10,237 | $8,838 |
| Net Loss | $(18,401) | $(16,253) |
| Net Loss Attributable to Ironwood | $(18,401) | $(15,924) |
| Net Loss Per Share (Basic & Diluted) | $(0.19) | $(0.25) |
| Cash and Cash Equivalents (End of Period) | $46,214 | $75,314 |
| Available-for-Sale Securities | $174,355 | $203,706 |
| Total Current Assets | $229,052 | $259,075 |
| Total Current Liabilities | $60,532 | $64,426 |
| Accumulated Deficit | $(385,941) | $(367,540) |
Liquidity: As of March 31, 2011, the company held approximately $220.6 million in unrestricted cash, cash equivalents, and available-for-sale securities. Management believes these resources, combined with potential future milestone payments, will fund operations through at least 2014.
Material Changes vs. Prior Period
- Revenue Increase: Collaborative revenue increased by 15.8% ($1.4 million) primarily due to the recognition of revenue from a $19.0 million milestone payment received from Almirall in November 2010 and increased recognition from the Astellas agreement.
- Operating Expenses: Total operating expenses rose 23.3% to $28.8 million.
- R&D Expenses: Increased 11.4% to $19.6 million. This was driven by higher compensation, share-based compensation, and a $3.2 million upfront payment for a new collaboration with Protagonist Therapeutics. These increases were partially offset by a $4.6 million decrease in Phase 3 clinical trial costs for linaclotide as trials concluded in late 2010.
- G&A Expenses: Increased 59.4% to $9.2 million, largely due to increased headcount, share-based compensation, and costs associated with building commercial infrastructure.
- Discontinued Operations: Net loss from discontinued operations was zero in Q1 2011 compared to a loss of $1.8 million in Q1 2010, reflecting the sale of the Microbia subsidiary in September 2010.
- Cash Flow: Net cash used in operating activities was $23.9 million, a slight improvement from $26.6 million in the prior year. Investing activities provided $25.2 million due to the sale and maturity of securities, whereas the prior year saw a significant use of cash for investing activities related to the IPO proceeds.
Guidance, Outlook, and Risks
- Outlook: The company expects to continue incurring significant operating losses for the foreseeable future. It anticipates submitting a New Drug Application (NDA) for linaclotide to the FDA in the third quarter of 2011.
- Accounting Changes: Effective January 1, 2011, the company adopted ASU 2009-13 (Multiple-Deliverable Revenue Arrangements) and ASU 2010-17 (Milestone Method). These changes allow for the recognition of milestone revenue in full upon achievement if the milestone is substantive, rather than amortizing it over the performance period.
- Risks:
- Regulatory Approval: Success is heavily dependent on FDA approval of linaclotide, which is not guaranteed. The FDA may require additional studies or impose restrictions.
- Manufacturing: The company relies on third-party contract manufacturers for API and finished product. Any failure to meet quality standards or supply requirements could delay approval or commercialization.
- Capital Requirements: While cash is sufficient through 2014, the company may need additional funding for commercialization or further pipeline development.
- Competition: The IBS-C and CC markets face competition from existing therapies and new entrants.
- Unusual Items: The company recorded a $3.2 million R&D expense related to a new collaboration with Protagonist Therapeutics, including a $2.8 million upfront payment.
Key Facts for Investor Verification
- Verify the status of the NDA submission for linaclotide, expected in Q3 2011, and any communications from the FDA regarding the application.
- Monitor the execution of commercial supply agreements with contract manufacturers (PolyPeptide Laboratories and Roche Colorado Corporation) to ensure capacity for potential launch.
- Track the recognition of deferred revenue from collaboration agreements (Forest, Almirall, Astellas) and the achievement of future milestones.
- Assess the burn rate and cash runway, specifically whether the $220.6 million in liquid assets will suffice through 2014 without additional equity raises.
- Review the progress of the Protagonist Therapeutics collaboration and the integration of its pipeline into Ironwood's R&D strategy.